In the first clinical study in this context, Hope et al. reported an increase in PSMA expression in prostate cancer metastases along with an increase in the number of lesions visualized using [68Ga]PSMA-11 PET/magnetic resonance imaging (MRI)following inhibition of the androgen receptor, albeit based on only one patient with castration-sensitive metastatic PCa [7]. The gene discussed is FOLH1; the disease is prostate carcinoma.